Skip to main content
Clinical Trials/NCT00448175
NCT00448175
Completed
Phase 4

Overactive Bladder Innovative Therapy Trial

Uroplasty, Inc1 site in 1 country100 target enrollmentJune 2006

Overview

Phase
Phase 4
Intervention
Urgent PC Neuromodulation System
Conditions
Overactive Bladder
Sponsor
Uroplasty, Inc
Enrollment
100
Locations
1
Primary Endpoint
Frequency of Voids at 12 Weeks
Status
Completed
Last Updated
12 years ago

Overview

Brief Summary

The purpose of this study is to compare percutaneous tibial nerve stimulation (PTNS) to drug therapy for the treatment of symptoms of overactive bladder (OAB).

Registry
clinicaltrials.gov
Start Date
June 2006
End Date
October 2008
Last Updated
12 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Is at least 18 years of age
  • Experiences OAB with a voiding frequency of at least 8 times per day
  • Is ambulatory and able to use a toilet independently and without difficulty

Exclusion Criteria

  • On OAB pharmacotherapy within the previous month
  • Primary complaint is stress urinary incontinence
  • Has pacemaker or implantable defibrillator
  • Has history of heart problems
  • Has nerve damage or neuropathy
  • Has gastric or urinary retention
  • Has uncontrolled narrow-angle glaucoma
  • Has known sensitivity to drug ingredients
  • Is pregnant or planning to become pregnant during the trial

Arms & Interventions

Urgent PC treatment arm

Intervention: Urgent PC Neuromodulation System

Urgent PC treatment arm

Intervention: Tolterodine

Outcomes

Primary Outcomes

Frequency of Voids at 12 Weeks

Time Frame: Baseline to 12 weeks

To demonstrate that the Urgent PC system is as effective as or more effective (noninferior) than tolterodine (Detrol LA) in changing the frequency of urinary voids per day after 12 weeks of therapy. The voiding diaries completed at 12 weeks were compared to the baseline voiding diaries.

Secondary Outcomes

  • Urge Incontinence Episodes at 12 Weeks(12 weeks)
  • Volume Voided at 12 Weeks(12 weeks)
  • OAB Quality of Life at 12 Weeks(12 weeks)
  • Known Side Effects Through 12 Weeks(12 weeks)

Study Sites (1)

Loading locations...

Similar Trials